⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024Open Access

Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Candace L. Haddox Michael J. Nathenson Emanuele Mazzola Jia‐Ren Lin Joanna Bagińska Allison Nau Jason L. Weirather Edwin Choy Adrián Mariño‐Enríquez Jeffrey A. Morgan Gregory M. Coté Priscilla Merriam Andrew J. Wagner Peter K. Sorger Sandro Santagata Suzanne George

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 1. Change in sum of longest tumor diameters across response assessments in liposarcoma and UPS/Other cohorts.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Haddox et al. (2024) studied this question.

synapsesocial.com/papers/68e7103bb6db643587689f61 https://doi.org/10.1158/1078-0432.25515982.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates2024
2Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates2024
3Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates2024
4Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates2024
5Figure S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024

More related papers

Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort2024
Table S4 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024